149
Participants
Start Date
December 31, 2013
Primary Completion Date
May 31, 2015
Study Completion Date
June 30, 2015
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
Placebo
placebo
P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
P2B001 site Chicago, Chicago
P2B001 Site Birmingham, Birmingham
P2B001 Site Los Angeles, Los Angeles
P2B001 Site Aurora, Aurora
P2B001 Manchester, Manchester
P2B001 Site New Haven, New Haven
P2B001 Site Boca Raton, Boca Raton
P2B001 Site Port Charlotte, Port Charlotte
P2B001 Site Tampa, Tampa
P2B001 Site Augusta, Augusta
P2B001 Site Kansas City, Kansas City
P2B001 Site Boston, Boston
P2B001 Site west Bloomfield, West Bloomfield
P2B001 Site Golden Valley, Golden Valley
P2B001 Site Camden, Camden
P2B001 Site New Brunswick, New Brunswick
P2B001 site Commack, Commack
P2B001 Site New York, New York
P2B001 Site Durham, Durham
P2B001 Site Cincinnati, Cincinnati
P2B001 Site Toledo, Toledo
P2B001 Site Tulsa, Tulsa
P2B001 Site Houston, Houston
P2B001 Site Roanoke, Roanoke
P2B001 Site Rambam Israel, Haifa
P2B001 Site Belinson, Pethch Tikva
P2B001 Site Sheba Medical Center, Ramat Gan
P2B001 Site Asaf Harofe, Rishon LeZiyyon
P2B001 Site Sourasky Medical Center, Tel Aviv
Lead Sponsor
Pharma Two B Ltd.
INDUSTRY